AAN 2019 Plenary Session Highlights Research With Implications for Patient Care From Multiple Society Meetings

Related Articles:

• Long-Term Efficacy for Parkinsonism and Safety of Zonisamide in Patients With Lewy Body Dementia Examined May 8, 2019 The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019. PHILADELPHIA — Zonisamide showed long-term efficacy for parkinsonism and safety in patients…
• Clonazepam for probable REM sleep behavior disorder in Parkinson’s disease: A randomized placebo-controlled trial. April 30, 2019 Related ArticlesClonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. J Neurol Sci. 2019 Apr 23;401:81-86 Authors: Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B Abstract BACKGROUND: Clonazepam is considered to be a first-line treatment for rapid eye movement sleep-related behavior disorder (RBD) in Parkinson's disease (PD). The purpose of this…
• Reply To: Isradipine Phase 3 Study Results Expected Soon (Result: FAIL) May 2, 2019 And another study disappoints.... https://www.eurekalert.org/pub_releases/2019-05/aaon-bpd042919.php Blood pressure drug shows no benefit in Parkinson's disease PHILADELPHIA - A study of a blood pressure drug does not show any benefit for people with Parkinson's disease, according to findings released today that will be presented at the American Academy of Neurology's 71st Annual Meeting in Philadelphia, May 4 to 10, 2019. The drug…
• Amantadine May Optimize Levodopa Regimen in Parkinson Disease Treatment May 8, 2019 The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019. PHILADELPHIA, PA — Long-term adjunctive amantadine (Gocovri®, Adamas Pharmaceuticals) treatment for individuals…
• Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. April 26, 2019 Related ArticlesSafety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS One. 2019;14(4):e0214364 Authors: Novak P, Pimentel Maldonado DA, Novak V Abstract Parkinson disease (PD) is associated with cognitive impairment. We aimed to determine the effects of intranasal insulin (INI) on cognition and motor performance in PD.…
• CVT-301 Improves Movement when Parkinson’s Symptoms Re-emerge During Day, Trial Shows June 9, 2017 CVT-301 significantly improves movement in Parkinson’s disease patients at times of the day when the impact of other therapies diminishes, according to a Phase 3 clinical trial. The impact of a Parkinson’s treatment varies during the day. It is often most effective right after a patient takes it, and least effective when much of its punch has worn off hours…
• SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. March 29, 2019 SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019 Mar 27;: Authors: Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, Ochudlo S, Banach M, Pagan F, Flatau-Baqué B, Csikós J, Cairney CJ, Blitzer A Abstract OBJECTIVE: This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic…
• #AANAM – Opicapone Can Prolong ‘On-Time’ Levopoda Provides, Data from Phase 3 Trials Show May 6, 2019 Once-daily opicapone can prolong the time during which treatment with levopoda, a standard therapy, effectively prevents motor symptom fluctuations in people with Parkinson’s disease, results from two international Phase 3 studies show. The findings, “Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies,” were presented during the 2019 Annual Meeting of the American Academy of Neurology (AAN), now…
• Study proves the effectiveness of Parkinson’s drug apomorphine May 11, 2017 Results from the 12-week TOLEDO study – which tested the effectiveness of APO-go®/MOVAPO® (apomorphine) on Parkinson’s patients whose symptoms could not be controlled with standard therapies – showed that patients treated with the infusion had a significantly greater improvement in ‘off’ time, compared with those taking the placebo. The reduction in ‘off’ time was achieved without an increase in dyskinesias and…
• Memantine for dementia. March 21, 2019 Related ArticlesMemantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3:CD003154 Authors: McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J Abstract BACKGROUND: Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is…
• #AAN2018: Biogen’s BIIB054 Shows Positive Data in Phase 1 Parkinson’s Trial April 18, 2018 Parkinson’s treatment candidate BIIB054 was well-tolerated and had a favorable pharmacological profile in preliminary Phase 1 clinical results. Biogen will present those results at the 2018 American Academy of Neurology ANN Annual Meeting in Los Angeles, California, April 21-27. Parkinson’s News Today will be covering the conference. The presentation “Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of AntiAlpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease,” will be…
• Recently published results of a GDNF intraputaminal infusion clinical trial March 5, 2019 A clinical trial, is by definition an experiment or a test — an effort to determine if something works, or doesn’t.  Sometimes, although the intended outcome of a clinical trial may fall short of expectations, the results are nevertheless intriguing and may spark additional avenues of investigation. Such is the case in a clinical trial of glial cell line derived…
• #AANAM – Promising Blood Pressure Medicine Fails to Slow Parkinson’s Progression, Trial Results Show May 10, 2019 In contrast to what was observed in mice, a hypertension medicine called Dynacirc (isradipine) failed to slow Parkinson’s disease progression in humans, according to Phase 3 clinical trial results. However, “the study did not fail,” according to Tanya Simuni, MD, who presented “A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III):…
• Nocebo response in Parkinson’s disease: A systematic review and meta-analysis. May 20, 2019 Nocebo response in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2019 Apr 20;: Authors: Leal Rato M, Duarte GS, Ferreira AN, Alves M, Mainoli B, Teodoro T, Mestre TA, Costa J, Ferreira JJ Abstract OBJECTIVE: To estimate the magnitude of the nocebo response in Parkinson's disease and explore possible associations with study characteristics. METHODS: Databases were searched…
• Finding a Better Way in Clinical Trials November 8, 2017 Fear about receiving the placebo is one of the biggest barriers to drug trial recriutment. In this article by Elly Earls in Pharma Technology Focus, Tom Isaacs comments on new trial designs which aim to reduce the number of people in the placebo groups. Concern about receiving the placebo is one of the biggest barriers to clinical trial recruitment. It’s…
• Sumitomo Dainippon Seeks Japanese Approval for Trerief to Treat Parkinsonism in Dementia Patients September 7, 2017 Sumitomo Dainippon Pharma has asked Japanese authorities to approve its Trerief (zonisamide) as a new therapy for parkinsonism in dementia patients with Lewy bodies, the company announced in a press release. Trerief went on sale in Japan in March 2009 as a treatment for Parkinson’s patients who saw insufficient results with levodopa and other Parkinson’s-specific drugs. After a 2013 expansion of its original approval,…
• Opicapone Superior to Comtan in Providing Motor Benefits to Parkinson’s Patients, Phase 3 Study Shows August 22, 2018 Once-daily treatment with opicapone provides continued reductions of off periods in Parkinson’s patients taking levodopa, Neurocrine Biosciences’ Phase 3 clinical study shows. The findings also reveal that opicapone’s effectiveness was superior to that of Comtan (entacapone, marketed by Novartis). The results were presented in three scientific posters at the 2018 World Congress on Parkinson’s Disease and Related Disorders (IAPRD), taking place in Lyon, France.…
• #AANAM — Investigational VY-AADC01 Gene Therapy Provides Benefits for Parkinson’s Patients, Phase 1 Data Show May 7, 2019 A single-dose infusion of VY-AADC01, an investigational gene therapy, improves motor function and reduces the need for antiparkinsonian medications in advanced Parkinson’s disease patients, results from the Phase 1 PD-1102 clinical trial show. Trial findings were presented in a scientific poster, titled “PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and…
• Levodopa Shows No Disease-modifying Effects in Parkinson’s, Study Finds January 29, 2019 Levodopa/carbidopa treatment is effective in managing Parkinson’s motor symptoms, but does not protect against disease progression among patients with early disease, a study shows. The research, “Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease” was published in The New England Journal of Medicine. Levodopa is the main treatment for Parkinson’s disease. However, neurologists might delay prescribing levodopa for different reasons, including…
• Adjunctive Therapy With Inhaled Levodopa Demonstrates Safety in Parkinson Disease May 17, 2019 Combined single inhaled doses of CVT-301 (inhaled levodopa) and oral carbidopa/levodopa therapy taken during early morning OFF symptoms demonstrated tolerability and lack of serious adverse events according to research published in Parkinsonism & Related Disorders. This randomized, double-blinded, 2-way crossover study included 36 individuals (mean age, 62.9 years) with Parkinson disease who self-administered either CVT-301 (84 mg) or placebo during…